Stem Cell Transplant or Cellular Therapy - Allogeneic

KNIGHT CANCER Institute
OHSU

Allogeneic

AML/MDS/ ALL

AML Only

IRB# 17622
Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant

IRB# 21238
A randomized open label phase 3 study evaluating the safety and efficacy of venetoclax in combination with azacitidine after allogenic SCT in subjects with AML

AML/MDS/ALL

IRB# 20708
A Multicenter, Phase 1b Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with TregGraft, a T-cell Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells

IRB# 21456
A Phase 1/2 Study to Evaluate the Safety and Efficacy of JSP191 in Combination with a Reduced Intensity Conditioning Regimen of Low Dose Radiation and Fludarabine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplantation

EBV

IRB# 20379
A Phase 2 Study of Tabelceluecel for Solid Organ or Allogeneic stem cell transplant Subjects with Epstein Barr Virus associated Post Transplant Lymphoproliferative Disease after failure of Rituximab or Rituximab and chemotherapy. All Ages.

IRB# 22428
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases

Severe Aplastic Anemia

IRB# 16943
BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants

Multiple Diseases

IRB# 19907
BMT CTN 1702
Clinical Transplant Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation

IRB# 20577
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality after Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients with Hematological Diseases

IRB# 21119
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients with Hematological Malignancies

Cellular Therapy

B-Cell Malignancies

IRB# 19760
A Phase 1/2 Study of Allogeneic CRISPR engineered T Cells in patients with B cell malignancy

IRB# 22043
A Phase I Study of FT819 in Subjects with B-cell Malignancies

IRB# 21691
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.

IRB# 21983
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients with Relapsed/Refractory Non–Hodgkin Lymphoma of B-Cell Origin

IRB# 21807
Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Stem Cell Transplant.

Solid Tumor

IRB# 21423
A Phase 1/2 Study of RTX-240 Monotherapy

Multiple Myeloma

IRB# 20759
A Phase 1 Dose Escalation and Cohort Expansion Study of Safety and Efficacy of Anti-BCMA Allogeneic CRISPR Cas-9-Engineered T Cells (CTX120) in Subjects with Relapsed or Refractory Multiple Myeloma

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/cancer/knight.php

03/21/2021